课题基金 / 基金详情

Discovery of novel benzimidazole resistance mechanisms

Discovery of novel benzimidazole resistance mechanisms
发现新的苯并咪唑耐药机制
批准号:
10190824
负责人:
Erik Christian Andersen
金额:
$69.64万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-07-01 至 2025-06-30

项目摘要

项目成果

Erik Christian Andersen的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project summary: Parasitic nematodes impose a massive health and economic burden across much of the developing world, infecting over one billion people worldwide. The morbidity and mortality inflicted by these devastating pathogens is partly curtailed by mass drug administration (MDA) programs that depend on the continued efficacy of a limited portfolio of anthelmintic drugs. Benzimidazole (BZ) compounds are a widely used class of broad-spectrum anthelmintics that are an indispensable component of this limited chemotherapeutic arsenal. The prospects of BZ resistance pose a serious threat to the future success of nematode control programs. These prospects have been realized in the veterinary domain following intensive BZ use and are predicted to materialize in human medicine with increased selection caused by expanded MDA. Early detection of resistance-associated alleles in nematode parasite populations is essential to the goal of slowing anthelmintic resistance and extending the lifespan of this critical drug class. Based on research in the free-living nematode Caenorhabditis elegans from thirty years ago, parasitic nematode researchers focus on one BZ target, a nematode-specific beta-tubulin. Despite this knowledge, it is still a complete mystery (1) whether any alleles cause resistance (i.e. go beyond correlation), (2) the nematode tissues that are sensitive to BZ poisoning, and (3) the drug-target interactions that cause resistance. In Haemonchus contortus, we have collected both validated sensitive and resistance samples, and longitudinal samples where resistance has developed over time. These samples are not available in any human parasitic nematode species. Using quantitative resistance assays on these resources, we have shown that BZ resistance goes well beyond this single beta- tubulin target. However, we do not know these independent resistance mechanisms in C. elegans or parasite species. In Aim 1, we will test explicitly whether alleles correlated with resistance in parasites actually cause resistance, test the fitness effects of these alleles, identify the tissues targeted by BZ, and characterize the molecular mechanism for how beta-tubulin in affected by benzimidazoles. In Aim 2, we will discover beta- tubulin independent mechanisms of resistance using the tractable C. elegans model nematode. In Aim 3, we will expand our results to H. contortus where genomic and validated strain resources enable discoveries of conserved resistance mechanisms. It is not possible in any parasitic nematode species to accomplish these goals. New discoveries are possible only through this interplay between the model nematode C. elegans and the tractable veterinary parasitic nematode H. contortus. Our results will have direct impacts on how treatments are administered and resistance is monitored in human parasitic nematodes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetic and genomic tools for C. briggsae research
  • 批准号:
    10371532
  • 项目类别:
  • 资助金额:
    $24.26万
  • 财政年份:
    2022
  • 负责人:
    Erik Christian Andersen
  • 依托单位:
Genetic and genomic tools for C. briggsae research
  • 批准号:
    10582658
  • 项目类别:
  • 资助金额:
    $18.84万
  • 财政年份:
    2022
  • 负责人:
    Erik Christian Andersen
  • 依托单位:
Discovery of Novel Benzimidazole Resistance Mechanisms
  • 批准号:
    10895749
  • 项目类别:
  • 资助金额:
    $71.14万
  • 财政年份:
    2020
  • 负责人:
    Erik Christian Andersen
  • 依托单位:
Discovery of novel benzimidazole resistance mechanisms
  • 批准号:
    10438771
  • 项目类别:
  • 资助金额:
    $68.21万
  • 财政年份:
    2020
  • 负责人:
    Erik Christian Andersen
  • 依托单位:
国内基金
海外基金
Albendazole增强肿瘤免疫抑制黑素瘤的作用与机制研究
  • 批准号:
    82003286
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    荔辉
  • 依托单位: